Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?

Christian Gisselbrecht; David Sibon

doi:10.1111/bjh.18468

Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?

Br J Haematol. 2023 Jan;200(1):13-14. doi: 10.1111/bjh.18468. Epub 2022 Sep 19.

Authors

Christian Gisselbrecht¹, David Sibon²

Affiliations

¹ Hopital Saint Louis, Paris Cité University, Paris, France.
² Lymphoid Malignancies Department, Henri Mondor University Hospital, AP-HP, Créteil, France.

Abstract

Treatment of relapsed/refractory diffuse large B-cell lymphoma remains a challenge with the advent of chimaeric antigen receptor CAR-T cell treatment. Whether or not eligibility criteria should replace the standard autologous transplantation is debated. By using PET-derived parameters, the report of Cherng and colleagues suggests that patients with positive residual mass can have a five-year survival of 54% with standard treatment.

Keywords: PET scan; autologous transplantation; non-Hodgkin's lymphoma; relapse refractory.

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma, Large B-Cell, Diffuse* / therapy
Lymphoma, Non-Hodgkin* / drug therapy
Neoplasm Recurrence, Local / therapy
Remission Induction
Stem Cell Transplantation
Transplantation, Autologous
Treatment Outcome